Loading
Latest filing published 24 Jan 2024 for Orchard Therapeutics plc.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
No signal scores available.
This profile gathers the share dealings of Bobby Gaspar in Orchard Therapeutics plc, where the filings describe the role as chief executive. Over a trading history stretching from 2 March 2020 to 24 January 2024, the count stands at 6 filings.
Both buying and selling appear: 1 purchase worth €10k, against 1 sale worth €58k. Sales outweigh purchases by €48k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants and 1 option exercise.
On 24 January 2024 came the latest disclosure, a transaction in Orchard Therapeutics plc. The latest purchase dates back some time: it was published 1,663 days ago, on 5 April 2022. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations